Cancer Research

CB1400, Patented By Canopus BioPharma, Prevents Tumor Growth And Enhances The Anti-Tumor Effects Of Cisplatin And Cetuximab (Erb

LOS ANGELES, California, June 19 /PRNewswire/-- Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with ...

Article - Anna Ohlden - Jun 19 2008 - 7:30am

Agendia Expands Laboratory Capacity At New Amsterdam Headquarters To Meet Increasing Demand For Services Worldwide

AMSTERDAM, Netherlands, June 19 /PRNewswire/-- Agendia BV has announced the official opening of the company's new headquarters yesterday at Amsterdam's Science Park at Watergraafsmeer, Kruislaan 406. The Grand Opening ceremony was officiated by ...

Article - Anna Ohlden - Jun 19 2008 - 1:30pm

Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) In Combination With Paclitaxel And Carbo

CALGARY, Alberta, June 20 /PRNewswire/-- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using i ...

Article - Anna Ohlden - Jun 20 2008 - 1:30am

How Measles Spreads Inside The Body

Measles, one of the most common contagious diseases, has been thought to enter the body through the surface of airways and lungs, like many other major viruses. Now, Mayo Clinic researchers and their collaborators say that's not the case, and some med ...

Article - News Staff - Jun 22 2008 - 1:02pm

Raptor Pharmaceuticals Corp. Announces Presentation At 5th International Cystinosis Conference 2008

NOVATO, California, June 23 /PRNewswire/--- Cystinosis Foundation Ireland to Host Event June 27-28, 2008 Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that Ted Daley, President of ...

Article - Anna Ohlden - Jun 23 2008 - 6:33am

CB1400, Patented By Canopus BioPharma, Enters Phase II Clinical Trials For The Prevention Of Mucositis In Patients With Cancer O

LOS ANGELES, June 23 /PRNewswire/-- Canopus BioPharma, Inc. (OTC: CBIA), is pleased to announce that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on ...

Article - Anna Ohlden - Jun 23 2008 - 7:30am

Your Genome Could Even Be Changing While You Read This

Researchers at Johns Hopkins say that epigenetic marks on DNA- chemical marks other than the DNA sequence- do indeed change over a person's lifetime, and that the degree of change is similar among family members. The team suggests that overall genome ...

Article - News Staff - Jun 24 2008 - 4:49pm

NICE Issues Final Appraisal Determination (FAD) Which Recommends Baraclude(R) (Entecavir) As A Treatment Option For Eligible Chr

UXBRIDGE, England, June 25 /PRNewswire/-- NICE (National Institute for Health and Clinical Excellence) has announced today, in its Final Appraisal Determination (FAD), that Baraclude(R) (entecavir) is recommended as an option for treatment of eligible pat ...

Article - Anna Ohlden - Jun 24 2008 - 6:32pm

Rosetta Genomics And Rabin Medical Center Announce A Collaboration Focused On MicroRNA-Based Diagnostics

REHOVOT, Israel and JERSEY CITY, New Jersey, June 25 /PRNewswire/--- Collaboration to Focus on the Development of MicroRNA-Based Tests for Oncology and Women's Health Indications Rosetta Genomics, Ltd. (Nasdaq: ROSG), announced today a collaboration ...

Article - Anna Ohlden - Jun 25 2008 - 8:32am

FDA Approves Quark IND For DGFi, An SiRNA Therapeutic Based On Silence Therapeutics' Unique Proprietary Chemistry

LONDON, June 25 /PRNewswire/--- Quark Pharmaceuticals to develop drug candidate for prevention and treatment of delayed graft function in kidney transplantation Silence Therapeutics plc (London AIM: SLN) today announces that the U.S. Food and Drug Adminis ...

Article - Anna Ohlden - Jun 25 2008 - 9:30am